AAPL316.22+2.83 (+0.90%) ▲|ABBV249.91-2.83 (-1.12%) ▼|ABT94.40-0.78 (-0.82%) ▼|ACN139.06+3.50 (+2.58%) ▲|ADBE222.65+1.71 (+0.77%) ▲|AMAT588.66+18.16 (+3.18%) ▲|AMD546.72+29.32 (+5.67%) ▲|AMGN363.62-4.37 (-1.19%) ▼|AMT165.00-0.04 (-0.02%) ▼|AMZN247.04+3.42 (+1.40%) ▲|AVGO401.11+12.42 (+3.20%) ▲|AXP346.72+10.33 (+3.07%) ▲|BA223.11-1.84 (-0.82%) ▼|BAC59.25+0.95 (+1.63%) ▲|BKNG175.52+1.23 (+0.71%) ▲|BLK1,019.68+29.34 (+2.96%) ▲|BMY57.94+0.40 (+0.70%) ▲|BNY152.26+2.12 (+1.41%) ▲|BRK-B495.45+0.66 (+0.13%) ▲|C139.57+2.18 (+1.59%) ▲|CAT938.39-9.69 (-1.02%) ▼|CL91.01-2.03 (-2.18%) ▼|CMCSA23.35+0.16 (+0.67%) ▲|COF200.10+8.15 (+4.25%) ▲|COP108.02-2.70 (-2.44%) ▼|COST912.97-40.16 (-4.21%) ▼|CRM162.50-4.08 (-2.45%) ▼|CSCO118.31+4.49 (+3.94%) ▲|CVS102.81-1.66 (-1.59%) ▼|CVX174.05-1.92 (-1.09%) ▼|DE592.90-3.84 (-0.64%) ▼|DHR195.98+5.21 (+2.73%) ▲|DIS96.17-0.53 (-0.55%) ▼|DUK125.26-1.53 (-1.21%) ▼|EMR137.80+1.32 (+0.97%) ▲|FDX310.84+1.08 (+0.35%) ▲|GD374.60+0.29 (+0.08%) ▲|GE359.04+3.01 (+0.85%) ▲|GEV1,075.26+4.27 (+0.40%) ▲|GILD134.84-0.98 (-0.72%) ▼|GM76.65+0.41 (+0.54%) ▲|GOOG356.24-2.47 (-0.69%) ▼|GOOGL358.89-3.03 (-0.84%) ▼|GS1,055.97+26.33 (+2.56%) ▲|HD338.73+2.52 (+0.75%) ▲|HON223.42+3.06 (+1.39%) ▲|IBM295.30-6.75 (-2.23%) ▼|INTC112.54+2.30 (+2.09%) ▲|INTU273.38+1.28 (+0.47%) ▲|ISRG411.55-3.55 (-0.86%) ▼|JNJ259.10-4.30 (-1.63%) ▼|JPM335.47+4.85 (+1.47%) ▲|KO82.63-0.77 (-0.92%) ▼|LIN525.56-2.11 (-0.40%) ▼|LLY1,216.95+1.12 (+0.09%) ▲|LMT518.26-9.70 (-1.84%) ▼|LOW213.00+0.15 (+0.07%) ▲|LRCX353.17+20.02 (+6.01%) ▲|MA523.20+4.21 (+0.81%) ▲|MCD276.49-1.76 (-0.63%) ▼|MDLZ58.30-1.18 (-1.98%) ▼|MDT82.39+0.38 (+0.46%) ▲|META631.48+28.36 (+4.70%) ▲|MMM155.34+0.64 (+0.41%) ▲|MO71.59-1.22 (-1.68%) ▼|MRK125.07-0.92 (-0.73%) ▼|MS222.13+4.06 (+1.86%) ▲|MSFT384.36+1.02 (+0.27%) ▲|MU991.64+42.84 (+4.52%) ▲|NEE87.10-0.34 (-0.39%) ▼|NFLX75.47-0.12 (-0.16%) ▼|NKE42.78-0.11 (-0.26%) ▼|NOW108.84+1.06 (+0.98%) ▲|NVDA202.78-1.34 (-0.66%) ▼|ORCL144.22+3.73 (+2.66%) ▲|PEP137.86-4.64 (-3.25%) ▼|PFE24.25+0.20 (+0.83%) ▲|PG146.85-1.55 (-1.04%) ▼|PLTR129.04-3.18 (-2.41%) ▼|PM181.17-5.90 (-3.15%) ▼|QCOM191.11+4.55 (+2.44%) ▲|RTX195.20+0.29 (+0.15%) ▲|SBUX106.41+2.54 (+2.45%) ▲|SCHW101.91+0.21 (+0.21%) ▲|SO95.17-1.21 (-1.26%) ▼|SPG219.71+0.62 (+0.28%) ▲|T21.04-0.08 (-0.38%) ▼|TMO524.71+14.58 (+2.86%) ▲|TMUS181.48+1.34 (+0.74%) ▲|TSLA406.55+12.62 (+3.20%) ▲|TXN308.53+7.21 (+2.39%) ▲|UBER74.35+0.75 (+1.02%) ▲|UNH431.68+6.08 (+1.43%) ▲|UNP285.04+4.10 (+1.46%) ▲|UPS110.74+0.80 (+0.73%) ▲|USB61.90+0.90 (+1.48%) ▲|V348.20+0.67 (+0.19%) ▲|VZ42.24-0.21 (-0.49%) ▼|WFC86.91+1.35 (+1.58%) ▲|WMT112.21-0.89 (-0.79%) ▼|XOM137.46-3.67 (-2.60%) ▼|AAPL316.22+2.83 (+0.90%) ▲|ABBV249.91-2.83 (-1.12%) ▼|ABT94.40-0.78 (-0.82%) ▼|ACN139.06+3.50 (+2.58%) ▲|ADBE222.65+1.71 (+0.77%) ▲|AMAT588.66+18.16 (+3.18%) ▲|AMD546.72+29.32 (+5.67%) ▲|AMGN363.62-4.37 (-1.19%) ▼|AMT165.00-0.04 (-0.02%) ▼|AMZN247.04+3.42 (+1.40%) ▲|AVGO401.11+12.42 (+3.20%) ▲|AXP346.72+10.33 (+3.07%) ▲|BA223.11-1.84 (-0.82%) ▼|BAC59.25+0.95 (+1.63%) ▲|BKNG175.52+1.23 (+0.71%) ▲|BLK1,019.68+29.34 (+2.96%) ▲|BMY57.94+0.40 (+0.70%) ▲|BNY152.26+2.12 (+1.41%) ▲|BRK-B495.45+0.66 (+0.13%) ▲|C139.57+2.18 (+1.59%) ▲|CAT938.39-9.69 (-1.02%) ▼|CL91.01-2.03 (-2.18%) ▼|CMCSA23.35+0.16 (+0.67%) ▲|COF200.10+8.15 (+4.25%) ▲|COP108.02-2.70 (-2.44%) ▼|COST912.97-40.16 (-4.21%) ▼|CRM162.50-4.08 (-2.45%) ▼|CSCO118.31+4.49 (+3.94%) ▲|CVS102.81-1.66 (-1.59%) ▼|CVX174.05-1.92 (-1.09%) ▼|DE592.90-3.84 (-0.64%) ▼|DHR195.98+5.21 (+2.73%) ▲|DIS96.17-0.53 (-0.55%) ▼|DUK125.26-1.53 (-1.21%) ▼|EMR137.80+1.32 (+0.97%) ▲|FDX310.84+1.08 (+0.35%) ▲|GD374.60+0.29 (+0.08%) ▲|GE359.04+3.01 (+0.85%) ▲|GEV1,075.26+4.27 (+0.40%) ▲|GILD134.84-0.98 (-0.72%) ▼|GM76.65+0.41 (+0.54%) ▲|GOOG356.24-2.47 (-0.69%) ▼|GOOGL358.89-3.03 (-0.84%) ▼|GS1,055.97+26.33 (+2.56%) ▲|HD338.73+2.52 (+0.75%) ▲|HON223.42+3.06 (+1.39%) ▲|IBM295.30-6.75 (-2.23%) ▼|INTC112.54+2.30 (+2.09%) ▲|INTU273.38+1.28 (+0.47%) ▲|ISRG411.55-3.55 (-0.86%) ▼|JNJ259.10-4.30 (-1.63%) ▼|JPM335.47+4.85 (+1.47%) ▲|KO82.63-0.77 (-0.92%) ▼|LIN525.56-2.11 (-0.40%) ▼|LLY1,216.95+1.12 (+0.09%) ▲|LMT518.26-9.70 (-1.84%) ▼|LOW213.00+0.15 (+0.07%) ▲|LRCX353.17+20.02 (+6.01%) ▲|MA523.20+4.21 (+0.81%) ▲|MCD276.49-1.76 (-0.63%) ▼|MDLZ58.30-1.18 (-1.98%) ▼|MDT82.39+0.38 (+0.46%) ▲|META631.48+28.36 (+4.70%) ▲|MMM155.34+0.64 (+0.41%) ▲|MO71.59-1.22 (-1.68%) ▼|MRK125.07-0.92 (-0.73%) ▼|MS222.13+4.06 (+1.86%) ▲|MSFT384.36+1.02 (+0.27%) ▲|MU991.64+42.84 (+4.52%) ▲|NEE87.10-0.34 (-0.39%) ▼|NFLX75.47-0.12 (-0.16%) ▼|NKE42.78-0.11 (-0.26%) ▼|NOW108.84+1.06 (+0.98%) ▲|NVDA202.78-1.34 (-0.66%) ▼|ORCL144.22+3.73 (+2.66%) ▲|PEP137.86-4.64 (-3.25%) ▼|PFE24.25+0.20 (+0.83%) ▲|PG146.85-1.55 (-1.04%) ▼|PLTR129.04-3.18 (-2.41%) ▼|PM181.17-5.90 (-3.15%) ▼|QCOM191.11+4.55 (+2.44%) ▲|RTX195.20+0.29 (+0.15%) ▲|SBUX106.41+2.54 (+2.45%) ▲|SCHW101.91+0.21 (+0.21%) ▲|SO95.17-1.21 (-1.26%) ▼|SPG219.71+0.62 (+0.28%) ▲|T21.04-0.08 (-0.38%) ▼|TMO524.71+14.58 (+2.86%) ▲|TMUS181.48+1.34 (+0.74%) ▲|TSLA406.55+12.62 (+3.20%) ▲|TXN308.53+7.21 (+2.39%) ▲|UBER74.35+0.75 (+1.02%) ▲|UNH431.68+6.08 (+1.43%) ▲|UNP285.04+4.10 (+1.46%) ▲|UPS110.74+0.80 (+0.73%) ▲|USB61.90+0.90 (+1.48%) ▲|V348.20+0.67 (+0.19%) ▲|VZ42.24-0.21 (-0.49%) ▼|WFC86.91+1.35 (+1.58%) ▲|WMT112.21-0.89 (-0.79%) ▼|XOM137.46-3.67 (-2.60%) ▼|
23.2 C
New York
Friday, July 10, 2026

Tag: research

newssourceFORcompanyinformationcontent1releasesmarket

Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor

Translational Data Presented at EACCI Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor

D-Bal Max 2025: Exploring the Science and Safety behind a Popular And Legal Dianabol Steroid For Muscle Growth

Glasgow, June 15, 2025 (GLOBE NEWSWIRE) --

In the quest for enhanced athletic performance and muscle growth, many fitness enthusiasts and bodybuilders turn to supplements. D-Bal Max has emerged as a noteworthy option that claims to replicate the muscle-building benefits of anabolic steroids, but with a natural and safer approach.

Airbus and McGill University are driving innovation in aerospace with an agreement for experiential learning and research

The initiative will help further propel Quebec and Canadian aerospace on the world stage, thus strengthening Montréal's position as one of the major international...

Seventh Presale Phase: Bitcoin Solaris Nears Public Launch with 10,000 TPS and 21M Supply Cap

TALLINN, Estonia, June 15, 2025 (GLOBE NEWSWIRE) -- Bitcoin Solaris (BTC-S), a next-generation blockchain built for speed, accessibility, and long-term sustainability, has officially entered the seventh phase of its token presale, with the public launch now just weeks away. With over $4.5 million already raised and more than 11,500 participants onboard, momentum is surging.

Investigational combination of first-in-class bispecific antibodies TALVEY®▼ (talquetamab) and TECVAYLI®▼ (teclistamab) shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary...

Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of GPRC5D and BCMA1 

Investigational combination of first-in-class bispecifics TALVEY® and TECVAYLI® shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease

Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of GPRC5D and BCMA Data signal...

Meta Develops Superintelligence Lab: Assessing AI’s Impact on Quantitative Models

**Title: Meta's Strategic Investment in AI: A Quantitative Perspective** **Introduction** Meta Platforms Inc. has announced a strategic $14.3 billion investment in a new artificial intelligence (AI)...

China, Central Asia make continuous efforts to deepen agricultural cooperation

BEIJING, June 15, 2025 /PRNewswire/ -- A report from People's Daily: ...

[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys™ gene therapy for Duchenne muscular dystrophy in non-ambulatory patients

Basel, 15 June 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new dosing restrictions, effective immediately, for ELEVIDYS™ (delandistrogene moxeparvovec), for non-ambulatory Duchenne muscular dystrophy (DMD) patients, irrespective of age, in both clinical and commercial settings. In the commercial setting, non-ambulatory patients should no longer receive Elevidys. In the clinical trial setting, enrolment and dosing of non-ambulatory patients will be immediately paused until additional risk mitigation measures (e.g. immune modulatory treatment) are implemented in the study protocol. Health authorities, investigators and physicians are being informed so that patient care can be quickly adjusted.

20 Textile Enterprises from Qingdao Attended AFF in Tokyo, Japan Hand in Hand

TOKYO, June 15, 2025 /PRNewswire/ -- A report from IQingDao: 2025 Asia Fashion Fair (AFF) grandly opened in Tokyo, Japan on June 9. Organized by...

FOX NEWS CHANNEL’S BRET BAIER LANDS FIRST INTERVIEW WITH ISRAELI PRIME MINISTER BENJAMIN NETANYAHU SINCE ISRAEL’S STRIKES ON IRAN ON SUNDAY, JUNE 15TH

NEW YORK, June 14, 2025 /PRNewswire/ -- FOX News Channel's Bret Baier will present a worldwide exclusive live interview with Israeli Prime Minister Bibi Netanyahu on...

Nimanode Surpasses Crypto Presales, Eyes 10X Growth Post-Launch as Major Investors Flock to the XRP DeFi Landscape

LEEDS, United Kingdom, June 14, 2025 (GLOBE NEWSWIRE) -- Nimanode, the first no-code AI agent platform built natively on the XRP Ledger (XRPL), is gaining momentum with its ongoing $NMA token presale.

No KYC. 100x Leverage. $50 Welcome Bonus. Crypto Futures Trading Made Easy on BexBack.

SINGAPORE, June 14, 2025 (GLOBE NEWSWIRE) -- With the price of Bitcoin fluctuating around $100,000, many analysts predict that the cryptocurrency market will remain in a state of high volatility for a long time. Holding spot positions may struggle to generate short-term profits in such conditions. As a result, 100x leverage futures trading has become the preferred tool for seasoned investors looking to maximize potential gains in this volatile market. BexBack Exchange is ramping up its efforts to offer traders unmatched promotional packages. The platform now features a 100% deposit bonus, a $50 welcome bonus for new users, and 100x leverage on cryptocurrency trading, providing exceptional opportunities for investors.

Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025

HAMPTON, N.J., June 14, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced data demonstrating that barzolvolimab profoundly improves angioedema at 52 weeks in the Company’s Phase 2 clinical trial in chronic spontaneous urticaria (CSU). Angioedema, characterized by swelling of the deeper dermal layers of the skin and mucous membranes, is a painful, debilitating symptom of CSU that has significant impact on quality of life. It commonly affects the face (lips and eyelids), hands, feet, and genitalia but can also involve the tongue, uvula, soft palate, and pharynx1.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsResearch

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers